CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 119 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $220,229,445 | -31.3% | 10,088,385 | 0.0% | 7.35% | -20.9% |
| Q2 2023 | $320,709,759 | +101.9% | 10,088,385 | +54.9% | 9.28% | +97.9% |
| Q1 2023 | $158,851,021 | -22.7% | 6,511,727 | 0.0% | 4.69% | -18.7% |
| Q4 2022 | $205,379,869 | +11.6% | 6,511,727 | 0.0% | 5.77% | +8.0% |
| Q3 2022 | $184,021,000 | +36.8% | 6,511,727 | +28.0% | 5.34% | +26.8% |
| Q2 2022 | $134,493,000 | -24.5% | 5,086,727 | 0.0% | 4.21% | +18.1% |
| Q1 2022 | $178,086,000 | -46.0% | 5,086,727 | -50.0% | 3.57% | +40.2% |
| Q4 2021 | $329,822,000 | +119.8% | 10,173,454 | +100.0% | 2.54% | +16.7% |
| Q3 2021 | $150,058,000 | -36.9% | 5,086,727 | -45.2% | 2.18% | +41.1% |
| Q2 2021 | $237,912,000 | +273.2% | 9,286,190 | +100.0% | 1.54% | +91.7% |
| Q1 2021 | $63,749,000 | -15.4% | 4,643,095 | +2.2% | 0.81% | -0.4% |
| Q4 2020 | $75,340,000 | – | 4,544,062 | – | 0.81% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,913,749,385 | 28.70% |
| Perceptive Advisors | 10,088,385 | $320,709,759 | 9.28% |
| Affinity Asset Advisors, LLC | 550,000 | $17,484,500 | 6.11% |
| Finepoint Capital LP | 492,545 | $15,658,006 | 5.42% |
| Paradigm Biocapital Advisors LP | 1,868,946 | $59,413,793 | 4.59% |
| BOONE CAPITAL MANAGEMENT LLC | 300,000 | $9,537,000 | 3.42% |
| Rock Springs Capital Management LP | 2,513,916 | $79,917,390 | 1.90% |
| Artal Group S.A. | 1,638,858 | $52,099 | 1.62% |
| Frazier Life Sciences Management, L.P. | 393,000 | $12,493,470 | 0.75% |
| Avidity Partners Management LP | 501,200 | $15,933,148 | 0.56% |